Sonelokimab in Psoriatic Arthritis

Trial
100%75%50%25%0%Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29Jun 30Jul 1Jul 2Jul 3Jul 4Jul 5Jul 6Jul 7Jun 24 • YES 58.0%Jun 25 • YES 73.0%Jun 29 • YES 73.6%Jun 30 • YES 73.6%Jul 1 • YES 63.1%Jul 2 • YES 83.1%Jul 3 • YES 83.1%Jul 4 • YES 9.7%Jul 5 • YES 9.7%Jul 6 • YES 40.5%Jul 7 • YES 93.2%
ResolvedYES
Oracle Evidence

Matched news2 items

All news
MLTX

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100 An analysis

Trial Results • Phase 3Matched sonelokimab, psoriatic, arthritis, versus
MLTX

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12 Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated

Trial Results • Phase 2Matched sonelokimab, arthritis